Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 2.11%155.960.0%$3291.50m
BIIBBiogen, Inc. 0.67%241.771.7%$680.21m
NVAXNovavax, Inc. -9.40%126.3992.9%$607.79m
AMGNAmgen, Inc. 1.00%224.261.3%$579.46m
BNTXBioNTech SE -4.73%118.360.0%$579.03m
GILDGilead Sciences, Inc. 1.85%61.791.0%$530.54m
VRTXVertex Pharmaceuticals, Inc. 0.75%229.461.9%$503.61m
REGNRegeneron Pharmaceuticals, Inc. 1.50%523.782.7%$497.28m
ILMNIllumina, Inc. 4.02%335.053.5%$392.30m
APVOAptevo Therapeutics, Inc. 0.62%44.0018.3%$243.82m
SGENSeagen Inc. 4.13%177.355.8%$183.23m
EXASEXACT Sciences Corp. 3.74%125.5819.6%$179.60m
ALXNAlexion Pharmaceuticals, Inc. -0.58%121.402.0%$148.56m
HALOHalozyme Therapeutics, Inc. 2.48%40.0718.4%$137.37m
SRNESorrento Therapeutics, Inc. -2.32%8.011.4%$136.55m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.